1.Effect of sulodexide combined with dipyridamole on postoperative period of internal arteriovenous fistulae in patients with chronic renal failure complicating diabetes
Nan OUYANG ; Ziming WAN ; Zhengrong LI ; Xiaogang DU
Chongqing Medicine 2014;(15):1863-1865
Objective To observe the effect of sulodexide combined with dipyridamole on postoperative period of internal arterio‐venous fistula in the patients with chronic renal failure complicating diabetes .Methods 72 cases of chronic renal failure complica‐ting diabetes were randomly divided into two groups :sulodexide combined with dipyridamole group(group A) and dipyridamole group (group B) .Platelet ,fibrinogen(FIB) ,prothrombin time ,activated partial thromboplastin time ,triglyceride ,total cholesterol and hemortheological indexes were tested at different time points .The internal fistula patency ,blood flow volume after internal fis‐tula maturation and time of initial internal fistula use after internal arteriovenous fistula operationwere observed .‐Results (1)The patency rate of internal arteriovenous fistula in the group A was higher than that in the group B .(2) Compared with the group B , FIB and low‐shear rate of whole blood viscosity in the group A were decreased .(3)The time of internal fistula maturation in the group A was shortened ,but the blood flow volume had no significant difference between the two groups .Conclusion Sulodexide combined with dipyridamole is safe and effective for preventing the thrombogenesis after internal arteriovenous fistula operation ,its effect is superior to single dipyridamole .
2.Clinical characteristics of diabetic patients with metabolic syndrome and its components at 15 urban communities in Beijing
Hanjing FU ; Shenyuan YUAN ; Gang WAN ; Liangxiang ZHU ; Mingxia YUAN ; Guangran YANG ; Sufang PAN ; Xianglei BU ; Jiandong ZHANG ; Xueping DU ; Yuling LI ; Yu JI ; Xiaoning GU ; Yue LI ; Xueli CUI ; Wei BAI ; Yujie CHEN ; Ziming WANG ; Qingsheng ZHU ; Ying GAO ; Deyuan LIU ; Yuntao JI ; Ze YANG
Chinese Journal of General Practitioners 2011;10(6):390-393
Objective To study clinical characteristics of type 2 diabetic(T2D)patients with metabolic syndrome(MS)and its components in Beijing urban communities.Methods Totally,3295 T2D patients involved in a combined prospective diabetic management study from 15 urban communities in Beijing were classified as four groups, according to 2004 Chinese Diabetes Society's definition of MS, i. e, isolated T2D, T2D with one component of MS, T2D with two components of MS and T2D with three components of MS. Their clinical characteristics were analyzed. Results ( 1 ) Among 3295 T2D patients, 155 (4. 7% )were isolated T2D, 107 (32.6%) T2D with one component of MS, 1386 (42.1%) T2D with two components of MS and 679 (20.6%) T2D with three components of MS, with an overall 62.7% (2065/3295) of T2D patients complicated with MS. (2) In these T2D patients, the more components of MS they had, the higher body mass index (BMI), waist circumference, waist to hip circumference ratio (WHR),systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting serum levels of insulin and triglyceride (TG) and the lower level of high-density lipoprotein-cholesterol (HDL) were presented (P <0. 01 ). (3) Percentage of isolated T2D in women increased from 49. 0% (76/155) to 61.9% (420/679)of those with three components of MS ( P < 0 01 ), with increasing of components of MS. (4) Multiple logistic regression analysis showed that BMI, history of hypertension, decreased HDL, increased TG,increased blood pressure, all were risk factors for T2D patients complicated with MS. Conclusions Among T2D patients in urban communities of Beijing, 95.3% (3140/3295) of them complicated with one or more components of MS, and 61.9% (420/679) of them complicated with MS. So, community diabetic management must be implemented in an all-round way, including control of blood pressure, blood lipids,body weight and so on, in addition to control of blood sugar.
3.Prevalence of dyslipidemia in subjects with type 2 diabetes mellitus in Beijing urban communities:Beijing community diabetes study 8
Guangran YANG ; Shenyuan YUAN ; Hanjing FU ; Gang WAN ; Liangxiang ZHU ; Mingxia YUAN ; Sufang PAN ; Xianglei BU ; Jiandong ZHANG ; Xueping DU ; Yuling LI ; Yu JI ; Xiaoning GU ; Yue LI ; Xueli CUI ; Wei BAI ; Yujie CHEN ; Ziming WANG ; Shuyan CHENG ; Ying GAO ; Deyuan LIU ; Yipin WANG
Chinese Journal of General Practitioners 2012;(10):748-752
Objective To investigate the prevalence of dyslipidemia in subjects with type 2 diabetes mellitus in Beijing urban communities.Methods Total 3316 subjects with type 2 diabetes (age 20-80 years) were recruited from 15 urban community health centers in Beijing using a multi-stage random sampling approach.Dyslipidemia was diagnosed according to Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults:2007 version.Results Among 3316 diabetic subjects (1329 malesand 1987 females),75.6% (2506/3316) had dyslipidemia,the prevalence was 72.5% (964/1329)in men and 77.6% (1542/1987) in women.The prevalence of hypertriglyceridemia and hypercholesterolemia was 41.9% (1388/3316) and 48.1% (1595/3316),respectively.31.5% (1043/3316) subjects had high levels of low-density lipoprotein cholesterol (LDL-C) and 21.2% (703/3316) had low high-density lipoprotein cholesterol (HDL-C).Among all subjects with dyslipidemia only 22.9% (575/2506) took hypolipid agents.The overall blood lipid control rates of triglyceride (TG),total cholesterol (TC),LDL-C and HDL-C in 1393 subjects with dyslipidemia history were 48.0% (669/1393),17.4% (242/1393),30.9% (430/1393) and 75.8% (1056/1393),respectively.Diabetics with dyslipidemia had higher body mass index,waist circumference,blood pressure,plasma glucose and hemoglobin A1c.The prevalence of dyslipidemia in the overweight and uncontrolled-glucose group were 79.0% (1678/2125),78.9% (1756/2227),respectively.Logistic regression analysis showed that gender,age,body mass index and hemoglobin A1c were associated with dyslipidemia.Conclusions The prevalence of dyslipidemia in diabetic subjects in Beijing urban communities is high and less than one quarter patients take hypolipid agents.Age,body mass index and hemoglobin A1c are the risk factors of dyslipidemia in type 2 diabetic patients.
4.Current status of hypoglycemic drug use among 3297 adult patients with type 2 diabetes in 15 urban communities of Beijing:Beiiing Community Diabetes Study-7
Bin LI ; Hanjing FU ; Shenyuan YUAN ; Liangxiang ZHU ; Jinkui YANG ; Gang WAN ; Sufang PAN ; Mei YU ; Xianglei PU ; Jiandong ZHANG ; Xueping DU ; Yuling LI ; Yu JI ; Xiaoning GU ; Yue LI ; Xueli CUI ; Wei BAI ; Yujie CHEN ; Ziming WANG ; Qingsheng ZHU ; Ying GAO ; Deyuan LIU ; Yipin WANG
Chinese Journal of General Practitioners 2011;10(11):796-800
Objective To investigate current status of use of oral hypoglycemic drugs and insulin among adult patients with type 2 diabetes mellitus (T2DM) in urban community of Beijing.Methods In total,3297 T2DM patients aged more than 20 years from 15 urban communities of Beijing were studied.Their body weight,height,fasting plasma glucose level and glycosylated hemoglobin Alc (HbAlc) were measured.A door-to-door questionnaire survey on use of oral hypoglycemic drugs and insulin was conducted for them.All the T2DM patients surveyed were divided into four groups based on their received intervention.Results ①Of 3279 T2DM patients,454 (13.8%) received lifestyle intervention,971 (29.5%) used only one oral hypoglycemic drug,1179 (35.7%) with combined oral hypoglycemic drugs,and 693(21.0%) with insulin.②There was significant difference in average HbAlc among the four groups of T2DM patients with lifestyle intervention,only one oral hypoglycemic drug,combined oral hypoglycemic drugs,and insulin,with HbAI c of (7.0 ± 1.9) %,(7.1 ± 1.5) %,(7.4 ± 1.5 ) %,and (7.5 ± 1.5 ) %for them,respectively ( F =15.1,P < 0.01 ).Proportions of the T2DM patients with HbAlc equal to or higher than 7.0% were 32.2%,39.4%,52.1% and 59.5% for the four groups,respectively ( x2 =117.7,P < 0.01 ).③In the T2DM patients with lifestyle intervention,32.2% (146/454) of them with HbA1 c equal to or higher than 7.0% were untreated with any oral hypoglycemic drug.In those with only one oral hypoglycemic drug,39.4% (383/971) of them with HbAlc equal to or higher than 7.0% were not treated with combined oral hypoglycemic drugs and/or insulin.In those with combined oral hypoglycemic drugs,52.1% (614/1079) of them with HbAlc equal to or higher than 7.0% were not received combined insulin treatment.④ Fasting plasma glucose level,treatment strategies,postprandial 2-h blood glucose level and length of the illness were independent risk factors for HbAlc level equal to or higher than 7.0%,with odds ratio (OR) of 1.757,1.256,1.175 and 1.031,respectively.⑤ In 2843 T2DM patients with oral hypoglycemie drugs and/or insulin treatment,1494 (52.6% ) received biguanides and 693 received (24.4% )insulin,respectively.Conclusions More than half of adult patients with T2DM do not meet the target of glycemic control of HbAlc less than 7.0% in urban communities of Beijing,due to not active use of oral hypoglycemic drugs,and not timely adoption of combined use of oral hypoglycemic drugs and insulin therapy.
5.A patient with brachial artery pseudoaneurysm treated with ultrasound-guided and balloon- assisted injection of human fibrin sealant
Senlin QIAN ; Hui LI ; Ziming WAN
Chinese Journal of Nephrology 2024;40(1):53-55
The paper reports the treatment of a maintenance hemodialysis patient with pseudoaneurysm (PSA) caused by accidental injury of brachial artery during the puncture of internal fistula. The main treatment methods of PSA include surgical incision and repair, local pressure therapy, ultrasound-guided intraluminal thrombin injection, implantation of covered stent, coil embolization and so on, but they all have some defects. The patient was admitted to hospital due to poor fistula function, and the formation of brachial artery PSA was confirmed by color ultrasound. PSA was successfully treated with ultrasound-guided and balloon-assisted injection of human fibrin sealant. The fistula had good function 3 months after the operation.
6.Effect of poria cocos on gastrointestinal motility in mice
Min FENG ; Ziming JIA ; Ming WAN ; Bolin FAN ; Xiaoqiao TANG ; Wenhua CHENG ; Fanzhong SUN
Journal of Public Health and Preventive Medicine 2023;34(5):39-41
Objective To investigate the regulatory effect of poria cocos on gastrointestinal motility in mice. Methods A total of 130 Kunming mice were randomly divided into negative control group, low-dose and high-dose groups of raw poria cocos powder, low-dose and high-dose groups of cooked poria cocos powder, low-dose and high-dose groups of poria cocos surrogate culture powder, low-dose, medium-dose and high-dose groups of poria cocos water extract, and low-dose, medium-dose and high-dose groups of poria cocos alcohol extract, with 10 mice in each group. The animals were administered by gavage for 7 days, once a day. After the last administration, the intestinal propulsion function test and gastric solid emptying test were conducted to observe the regulating effect of poria cocos on gastrointestinal motility of mice. Results Compared with the negative control group, the small intestine propulsion rate in the low-dose group of poria cocos surrogate culture powder was significantly increased (P<0.01). Except the high-dose group of raw poria cocos powder, the other poria cocos groups had higher gastric residual rate (P<0.05). Conclusion Poria cocos does not promote intestinal propulsion of mice under normal physiological condition, but it can inhibit gastric empting and exert a moderating effect on gastrointestinal function in normal mice.
7.Inhibiting collagen I production and tumor cell colonization in the lung via miR-29a-3p loading of exosome-/liposome-based nanovesicles.
Yan YAN ; Cancan DU ; Xixi DUAN ; Xiaohan YAO ; Jiajia WAN ; Ziming JIANG ; Zhongyu QIN ; Wenqing LI ; Longze PAN ; Zhuoyu GU ; Fazhan WANG ; Ming WANG ; Zhihai QIN
Acta Pharmaceutica Sinica B 2022;12(2):939-951
The lung is one of the most common sites for cancer metastasis. Collagens in the lung provide a permissive microenvironment that supports the colonization and outgrowth of disseminated tumor cells. Therefore, down-regulating the production of collagens may contribute to the inhibition of lung metastasis. It has been suggested that miR-29 exhibits effective anti-fibrotic activity by negatively regulating the expression of collagens. Indeed, our clinical lung tumor data shows that miR-29a-3p expression negatively correlates with collagen I expression in lung tumors and positively correlates with patients' outcomes. However, suitable carriers need to be selected to deliver this therapeutic miRNA to the lungs. In this study, we found that the chemotherapy drug cisplatin facilitated miR-29a-3p accumulation in the exosomes of lung tumor cells, and this type of exosomes exhibited a specific lung-targeting effect and promising collagen down-regulation. To scale up the preparation and simplify the delivery system, we designed a lung-targeting liposomal nanovesicle (by adjusting the molar ratio of DOTAP/cholesterol-miRNAs to 4:1) to carry miR-29a-3p and mimic the exosomes. This liposomal nanovesicle delivery system significantly down-regulated collagen I secretion by lung fibroblasts in vivo, thus alleviating the establishment of a pro-metastatic environment for circulating lung tumor cells.